Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Overview

Journal Cancer Res Commun

Specialty Oncology

Date 2024 Nov 26

PMID 39591206

Authors

Maj K Kjeldsen

Morten Jorgensen

Dina Sofie B Gronseth

Martin Schonemann-Lund

Gitte-Bettina Nyvang

Charlotte Aaquist Haslund

Anja Oer Knudsen

Anne Krejbjerg Motavaf

Susanne Malander

Maarit Anttila

Gabriel Lindahl

Johanna Maenpaa

Maria Dimoula

Theresa L Werner

Trine Zeeberg Iversen

Sakari Hietanen

Lars Fokdal

Hanna Dahlstrand

Line Bjorge

Michael J Birrer

Mansoor R Mirza

Maria Rossing

Affiliations

Soon will be listed here.

Abstract

The irregular response to PARPi in HRD-positive and -negative tumors highlights the need for identifying additional biomarkers. This study explores the mutational landscape beyond HRD status in AOC, ultimately advancing precision oncology in future clinical practice.

References

Philip C, Laskov I, Beauchamp M, Marques M, Amin O, Bitharas J . Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 2017; 17(1):638. PMC: 5591502. DOI: 10.1186/s12885-017-3639-0. View

Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Ahmed R, Denman M, Steele C . Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun. 2021; 12(1):7064. PMC: 8642453. DOI: 10.1038/s41467-021-27291-8. View

Patch A, Christie E, Etemadmoghadam D, Garsed D, George J, Fereday S . Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521(7553):489-94. DOI: 10.1038/nature14410. View

Swisher E, Kwan T, Oza A, Tinker A, Ray-Coquard I, Oaknin A . Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun. 2021; 12(1):2487. PMC: 8093258. DOI: 10.1038/s41467-021-22582-6. View

Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae J, Fazel Darbandi S, Knowles D, Li Y . Predicting Splicing from Primary Sequence with Deep Learning. Cell. 2019; 176(3):535-548.e24. DOI: 10.1016/j.cell.2018.12.015. View

Horak P, Griffith M, Danos A, Pitel B, Madhavan S, Liu X . Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022; 24(5):986-998. PMC: 9081216. DOI: 10.1016/j.gim.2022.01.001. View

Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R . Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25):2416-2428. DOI: 10.1056/NEJMoa1911361. View

Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C . Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome. Comput Struct Biotechnol J. 2021; 19:4435-4446. PMC: 8379270. DOI: 10.1016/j.csbj.2021.08.007. View

Leman R, Muller E, Legros A, Goardon N, Chentli I, Atkinson A . Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer. Clin Cancer Res. 2023; 29(21):4419-4429. PMC: 10618649. DOI: 10.1158/1078-0432.CCR-23-0898. View

10.

Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A . Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC Cancer. 2014; 14:179. PMC: 4007824. DOI: 10.1186/1471-2407-14-179. View

11.

Korsholm L, Kjeldsen M, Perino L, Mariani L, Nyvang G, Kristensen E . Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity. JCO Precis Oncol. 2024; 8:e2300483. PMC: 10919475. DOI: 10.1200/PO.23.00483. View

12.

Werner B, Powell E, Duggan J, Cortesi M, Lee Y, Arora V . Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer. Mol Oncol. 2024; 18(11):2668-2683. PMC: 11547227. DOI: 10.1002/1878-0261.13710. View

13.

Carey J, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y . Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2017; 78(3):742-757. PMC: 5811386. DOI: 10.1158/0008-5472.CAN-17-1494. View

14.

Lorusso D, Mouret-Reynier M, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P . Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Int J Gynecol Cancer. 2023; 34(4):550-558. PMC: 10982633. DOI: 10.1136/ijgc-2023-004995. View

15.

Liu J, Barry W, Birrer M, Lee J, Buckanovich R, Fleming G . Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019; 30(4):551-557. PMC: 6503628. DOI: 10.1093/annonc/mdz018. View

16.

Willing E, Vollbrecht C, Vossing C, Weist P, Schallenberg S, Herbst J . Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation. Cancers (Basel). 2023; 15(13). PMC: 10341077. DOI: 10.3390/cancers15133445. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Wang Y, Bernhardy A, Cruz C, Krais J, Nacson J, Nicolas E . The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016; 76(9):2778-90. PMC: 4874568. DOI: 10.1158/0008-5472.CAN-16-0186. View

19.

Callens C, Rodrigues M, Briaux A, Frouin E, Eeckhoutte A, Pujade-Lauraine E . Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial. Oncogene. 2023; 42(48):3556-3563. PMC: 10673712. DOI: 10.1038/s41388-023-02839-8. View

20.

Gallyas Jr F, Sumegi B, Szabo C . Role of Akt Activation in PARP Inhibitor Resistance in Cancer. Cancers (Basel). 2020; 12(3). PMC: 7139751. DOI: 10.3390/cancers12030532. View